Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Trial Profile

Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2012

At a glance

  • Drugs Ticagrelor (Primary) ; Prasugrel
  • Indications Myocardial infarction; Thrombosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 29 Aug 2012 Actual patient numbers changed from 50 to 38 as reported by the abstract
    • 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 09 Apr 2012 Actual patient number added 50 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top